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Background and Aim. Rutin is a flavonol with neuroprotective activity. The aim of the present study is to investigate the role of the
glutamatergic system in the antidepressant-like effect of rutin in a mouse model of maternal separation (MS) stress focusing on
histological changes in the CA3 area of the hippocampus. Methods. Mouse neonates were exposed to MS paradigm 3 hours
daily from postnatal days (PND) 2 to 14. The control and MS mice were divided separately into 16 groups (n = 8) (8 groups for
each set) including mice that received normal saline, mice that received rutin at doses of 10, 50, and 100mg/kg, mice that
received NMDA at a dose of 150mg/kg, mice that received ketamine (NMDA antagonist) at a dose of 0.25mg/kg, mice that
received NMDA antagonist plus a subeffective dose of rutin, and mice that received NMDA plus an effective dose of rutin.
Forced swimming test (FST) was performed. Afterwards, the hippocampus was evaluated in cases of histopathological changes
as well as expression of NR2A and NR2B genes. Results. Rutin significantly reduced immobility time in the FST. The expression
of NR2A and NR2B subunits of NMDA receptor in MS mice was significantly higher than that in the control group. Rutin
significantly decreased the expression of NR2B and NR2A subunits in the hippocampus. The CA3 diameter and percentage of
dark neurons in the hippocampus of MS mice significantly decreased and increased, respectively, which partially reversed
following rutin administration. Conclusion. Rutin, partially, through a neuroprotective effect on the hippocampus exerted
antidepressant-like effect. We concluded that NMDA receptors, at least in part, mediated the beneficial effect of rutin.
1. Introduction
Depression is a multifactorial, high-economic burden and
chronic disease that affects 20% of the world population
and is considered as one of the top ten causes of mortality
[1, 2]. Current therapies commonly alter the monoamine
neurotransmitters in the CNS [3]. However, only about half
of the patients show adequate response to these drugs, and
many of them are leaving treatment due to side effects [4].
In recent years, researches have been focused on other factors
involved in the pathophysiology of depression other than
common monoamine pathways [1].
Maternal separation (MS) is an animal model designed to
induce stress in the early life [5]. MS is defined as the lack of
care, short-term care, or repeated separation from mothers
during early life. This type of stress can negatively affect the
development of the brain and subsequently lead to impair-
ment in social behavior. Infants under MS stress are prone
to development of anxiety, depression, memory loss, and
neurological disorders [6–8].
The hippocampus is a part of the brain’s limbic system
which plays an important role in regulating emotions [9].
Researchers have shown that people with depression have a
smaller hippocampal size [10]. Animal studies have also
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shown that depression induced by exposure to unpredictable
chronic stress is associated with a significant increase in the
hippocampal CA3 neurodegeneration [11]. Dystrophic
lesions of the hippocampal CA3 neurons have been reported
in rats with depressive-like behaviors [12].
Glutamate is a major excitatory neurotransmitter in the
CNS, which is involved in many physiological conditions
such as brain development, synaptic flexibility, memory,
and learning [13, 14]. Studies on mice exposed to chronic
stress have shown an increase in expression of hippocampal
NMDA receptor subunits [15]. For this reason, researchers
have considered NMDA receptors for possible therapeutic
aspects of depression. In this regard, it has been observed that
ketamine and other NMDA antagonists possessed antide-
pressant effects [16].
It has been well-known that natural compounds have an
important role in the management and treatment of depres-
sion [17, 18]. In this regard, previous studies have demon-
strated that flavonoids could attenuate the depressive-like
behaviors in animal models of depression [19, 20]. Rutin,
which is also known as rutoside and quercetin 3-O-rutino-
side, is a glycosidic compound [21]. Rutin is a flavonoid
compound found in many plants, including citrus fruits,
Buckwheat, leaves of Rheum species, and Asparagus [22–26].
To date, a wide range of biological activities have been pro-
posed for rutin including reduced permeability and fragility
of the capillaries, anti-inflammatory, antioxidant, and neuro-
protective activities [22, 27–29]. Preclinical studies have also
been shown that rutin has antidepressant effects [11]. Given
the abovementioned properties of rutin, as well as the fact
that the exact mechanisms of its beneficial effects have not
yet been determined, the present study is aimed at investigat-
ing the role of NMDA receptors in the antidepressant-like
effect of rutin with a focus on histological changes in the
hippocampus.
2. Material and Methods
2.1. Animals. Pregnant NMRI mice (first day of pregnancy)
(22–28 g weight) were used (Pasteur Institute, Tehran, Iran).
Mice were maintained in standard laboratory conditions
including 12 h light/12 h dark, 22 ± 1°C with equal access to
food and water.
Day of birth was considered as postnatal day (PND) 0.
From PND2, neonates were exposed to the maternal separa-
tion paradigm [5] for 3 hours daily until PND14. On PND14,
the infants were returned to their mother cages and kept
intact until day 21. From day 21, mice were isolated from
their mother and were then kept in cages in groups of 4 until
PND 60 (22–30 g weight). Control mice were kept in the
mother cage from PND0 to PND21 without manipulation
and were then kept in cages in groups of 4 from PND21
to PND60.
2.2. Drugs. The drugs used in this study were as follows: (1)
rutin, (2) ketamine (an NMDA antagonist), and (3) NMDA
(as NMDA agonist). All drugs were purchased from Sigma,
St Louis, MO, USA. All drugs were dissolved in 0.9% saline
in a volume of 10ml/kg and were administered intraperito-
neally (i.p.). The dose of each drug was adjusted according
to animal body weight (mg of drug/kg of body weight of mice).
2.3. Study Design. 128 male NMRI mice aged 60-61 days were
divided into 16 groups (n = 8). The groups were as follows:
group 1: control mice received normal saline at a dose of
10ml/kg; groups 2, 3, and 4: control mice received rutin at
the doses of 10, 50, and 100mg/kg, respectively; group 5:
MS mice received normal saline at a dose of 10ml/kg; groups
6, 7, and 8: MS mice received rutin at the doses of 10, 50, and
100mg/kg, respectively; group 9: control mice received
NMDA antagonist (ketamine) at a dose of 0.25mg/kg; group
10: MS group received ketamine at a dose of 0.25mg/kg;
group11: control mice received the NMDA at a dose of
150mg/kg; group 12: MS mice received the NMDA at a dose
of 150mg/kg; group 13: control mice received ketamine plus
a subeffective dose of rutin; group 14: MS group received
ketamine plus a subeffective dose of rutin; group15: control
Table 1: Primer sequences.
Name Sequence
Nr2A-F CTCAGCATTGTCACCTTGGA
Nr2A-R GCAGCACTTCTTCACATTCAT
Nr2B-F CTACTGCTGGCTGCTGGTGA
Nr2B-R GACTGGAGAATGGAGACGGCTA
H2afz-F TCATCGACACCTGAAATCTAGGA
H2afz-R AGGGGTGATACGCTTTACCTTTA
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Figure 1: Comparison of immobilization duration in forced
swimming test in experimental groups. Data are expressed as
mean ± SEM (ANOVA and Tukey post hoc test). ###P < 0:001
compared with the control group (normal), and ∗P < 0:05 and
∗∗∗ P < 0:001 in comparison with the MS group. $P < 0:05
compared with the MS group which received rutin at the dose
of 100mg/kg. MS: maternal separation.
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mice received the effective dose of rutin plus NMDA; and
group 16: MS mice received the effective dose of rutin plus
NMDA. We treated mice with NMDA (15min), ketamine
(60min), and rutin (60min) prior to the behavioral test. Dose
and time of drug administrations were chosen based on pre-
vious studies as well as our pilot study [30–32].
2.4. Forced Swimming Test (FST). FST is one of the valid and
common tests used for evaluation of depression in rodents.
In this experiment, a glass container (12 cm by 25 cm) is filled
to a height of 15 cm with water at 25°C. The animal was then
gently placed in water. The total compulsory swimming
course is 6 minutes, and the first two minutes are considered
to match the animal with the new conditions and the immo-
bilization time is recorded for the next 4 minutes [5]. In the
FST, an increase in immobility time reflects the inability of
mice to deal with an acute unescapable challenge expressing
the depressive-like behaviors.
2.5. Pathological Assessment. After the behavioral test, ani-
mals were killed by high doses of pentobarbital (60mg/kg,
i.p.). Cardiac perfusion was performed with 0.9% normal
saline and then with 4% paraformaldehyde in 0.1ml of cold
phosphate buffer (pH = 7:5), and then, the brain was dis-
sected out. After fixation, brain tissues were immersed in
10% formalin. Then, 5μm sections were taken from the
brains. The 5 sections taken from each brain were deparaffi-
nized and stained with H&E staining. Histological analysis
was performed under a light microscope, and then, images
were displayed by embedding a digital camera attached to a
computer monitor. Three fields were selected from each
slide, and the density of dark neurons and natural neurons
within the pyramidal layer of the CA3 region was estimated.
The thickness of the CA3 layer was determined by a pathol-
ogist using the ImageJ software.
2.6. Gene Expression of NMDA Receptor Subunits. At the end
of the experiment, the hippocampus was isolated and the
expression of NR2A and NR2B subunits of NMDA receptor
was assessed by Real-Time PCR. RNA was extracted with tri-
zol, and cDNA synthesis was performed using a kit (Yekta
Tajhiz, Iran). The PCR for each of the genes was in triplicate
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Figure 2: Comparison of the expression of NR2A and NR2B genes
in the hippocampus. Data are expressed as mean ± SEM (ANOVA
and Tukey post hoc test). ∗P < 0:05, ∗∗P < 0:01, and ∗∗∗ P <
0:001 in comparison with the control group. #P < 0:05, ##P < 0:01,
and ###P < 0:001 in comparison with the MS group. $P < 0:05 in
comparison with the MS group which received rutin at a dose of
10mg/kg. @P < 0:05 in comparison with the MS group which
received rutin at a dose of 100mg/kg. MS: maternal separation.
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Figure 3: Comparison of hippocampal CA3 region diameter in
experimental groups. Data are expressed as mean ± SEM (ANOVA
and Tukey post hoc test). ∗P < 0:05 and ∗∗P < 0:01 in comparison
with the control group. #P < 0:05 and ##P < 0:01 in comparison
with the MS group. @P < 0:05 in comparison with the MS group
which received rutin at the dose of 100mg/kg. MS: maternal
separation.
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and repeated twice. The specific primers were designed using
Primer3 Input (version 0.4.0), and H2afz gene as a normal-
izer was used to modify the expression level of the target
genes compared to the control group. Histone H2A variant,
H2afz, was used as normalizer gene, and variations in expres-
sion of each mRNA in comparison with H2afz were mea-
sured based on 2−ΔΔCt relative expression formula, as
described previously [33]. The sequences of primers are pre-
sented in Table 1.
2.7. Data Analysis. The results were analyzed by SPSS 16 soft-
ware. One-way ANOVA followed by Tukey’s posttest was used
for multiple comparisons. Significant differences were con-
sidered at P < 0:05. Results were expressed as mean ± SEM.
3. Results
3.1. Rutin Decreased the Immobility Time in the FST of MS
Mice.One-way ANOVA showed that there is a significant dif-
ference among the experimental groups (F ð15, 109Þ = 47:13
(P < 0:001)). The duration of immobilization of the MS mice
was significantly longer than that of the control group
(P < 0:001). The immobility time of the MS mice which
received rutin at a dose of 100mg/kg significantly decreased
in comparison with that of the MS group (P < 0:001).
The administration of ketamine (0.25mg/kg) significantly
decreased the immobility of MS mice in comparison with
the MS mice which received saline (P < 0:05). The dura-
tion of immobilization of the MS mice which received
rutin (10mg/kg) plus ketamine was not significantly different
from that of the MS group which received rutin alone. The
immobility time of the MS mice which received rutin
(100mg/kg) plus NMDA significantly increased in compari-
son with that of the MS group which received rutin alone
(P > 0:05, Figure 1).
3.2. Rutin Modulated the Gene Expression of NMDA Receptor
Subunits in the Hippocampus. One-way ANOVA showed
(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j) (k) (l)
(m) (n)
Figure 4: Representative features from the diameter of the CA3 region of the hippocampus pyramidal area. (a) Control, (b) MS, (c) rutin 10
(control), (d) rutin 10 (MS), (e) rutin 50 (control), (f) rutin 50 (MS), (g) rutin 100 (control), (h) rutin 100 (MS), (i) NMDA 150 (control), (j)
ketamine 0.25 (control), (k) NMDA 150 (MS), (l) ketamine 0.25 (MS), (m) rutin 10+ketamine (MS), and (n) rutin 100+NMDA (MS). H&E
staining (scale bar = 25micrometer).
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that there is a significant difference among the experimental
groups (F ð15, 49Þ = 9:24 (P < 0:001)). Based on the results,
the expression of NR2A subunit of NMDA receptor in the
MS mice is significantly higher than that in the control group
(P < 0:001, Figure 2). The expression of NR2A is significantly
lower in the MS mice which received rutin at the doses of 50
and 100mg/kg than in the MS group which received saline
(P < 0:05 and P < 0:001). The administration of ketamine
(0.25mg/kg) significantly decreased the expression of
NR2A in the MS group in comparison with the MS mice
which received saline (P < 0:05). The expression of NR2A
subunit of NMDA receptor in the MS mice which received
10mg/kg rutin plus ketamine is significantly lower than that
in the MS group which received rutin at a dose of 10mg/kg
alone (P < 0:05). The expression of NR2A in the MS group
which received 100mg/kg rutin and NMDA is significantly
higher than that in the MS group which received rutin at a
dose of 100mg/kg rutin alone (P < 0:05).
One-way ANOVA showed that there is a significant dif-
ference among the experimental groups (F ð15, 49Þ = 14:28
(P < 0:001)). The expression of NR2B subunit of NMDA
receptor in MS mice is significantly higher than that in the
control group (P < 0:01). The expression of NR2B subunit
is significantly lower in the MS mice which received rutin
at the dose of 100mg/kg than in theMS group which received
saline (P < 0:01). The expression of NR2B is significantly
lower in the MS mice which received 10mg/kg rutin plus
ketamine than in theMS group which received rutin at a dose
of 10mg/kg alone (P < 0:05), as well as in the MS group
which received 100mg/kg rutin plus NMDA than in the
MS group which received rutin at a dose of 100mg/kg alone
(P < 0:05).
3.3. Rutin Increased the Diameter of the CA3 Area of the
Hippocampus. One-way ANOVA showed that there is a
significant difference among the experimental groups
(F ð15, 48Þ = 10:26 (P < 0:001)). Based on the results
(Figures 3 and 4), hippocampal CA3 diameter is significantly
lower in the MS mice than in the control group (P < 0:05).
Hippocampal CA3 region diameter is significantly higher in
the MS mice which received rutin at doses of 10, 50
(P < 0:05), and 100 (P < 0:01) mg/kg than in the MS group
which received saline. Hippocampal CA3 region diameter
in the MS mice which received rutin (10mg/kg) plus keta-
mine is not significantly different from the MS group which
received rutin at a dose of 10mg/kg alone (P > 0:05). Hippo-
campal CA3 region diameter in the MS group which received
rutin (100mg/kg) plus NMDA is significantly increased in
comparison with the MS group which received 100mg/kg
rutin alone (P < 0:05).
3.4. Rutin Decreased the Percent of Dark Neurons in the
Pyramidal Area of the Hippocampus. One-way ANOVA
showed that there is a significant difference among the exper-
imental groups (F ð15, 49Þ = 11:21 (P < 0:01)). Results
showed that the percentage of dark neurons in the MS mice
is significantly higher than that in the control group
(P < 0:01, Figures 5 and 6). The percentage of dark hippo-
campal neurons in the MS mice which received rutin at the
doses of 50 and 100mg/kg is significantly lower than that
in the MS group (P < 0:01). Coadministration of rutin
(10mg/kg) plus ketamine in the MS group had no significant
effect compared to the rutin-received counterpart (P > 0:05).
Furthermore, coinjection of rutin (100mg/kg) and NMDA in
the MS group did not significantly change the percentage of
dark hippocampal neurons in comparison with theMS group
which received rutin at a dose of 100mg/kg alone (P > 0:05).
4. Discussion
According to the results of the present study, exposure of
mice at early life into a stressful condition induced by mater-
nal separation paradigm was associated with depression-like
behavior during adolescence. Maternally separated mice
showed an increase in immobility time in the forced swim-
ming test (FST). The FST is one of the most valid and com-
mon tests use for assessing depressive-like behaviors in
rodents [34]. According to Seligman’s theory of helplessness,
if the animal is exposed to constant stress situations and has
no way to escape, it gradually loses hope of escape [35]. The
FST reflects one stage of desperate behavior in which
depressed mice show greater immobility time [32, 36]. Previ-
ous studies have shown that reserpine-induced depression
[37] and chronic stress-induced depression models are associ-
ated with an increase in the immobility time in the FST [38,
39]. Our findings are in line with aforementioned studies in
whichMS stress is accompanied with an increase in the immo-
bility time in the FST in comparison with the control mice.
Previous studies have shown that flavonoids exerted neu-
roprotective effects and attenuated the depressive-like behav-
iors [40, 41]. In this regard, various pharmacological effects
have been reported for rutin including neuroprotective,
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Figure 5: Percentage of dark hippocampal neurons in experimental
groups. Data are expressed as mean ± SEM (ANOVA and Tukey
post hoc test). ∗∗P < 0:01 in comparison with the control group.
##P < 0:01 in comparison with the MS group. MS: maternal
separation.
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antioxidative stress, anti-neuroinflammatory, antidiabetic,
and nephroprotective effects [42–46]. In 2017, Parashar
et al. demonstrated that rutin possessed antidepressant- and
anxiolytic-like effects in rats exposed to unpredictable
chronic stress paradigm [11]. Yusha’u et al. showed that rutin
decreased the duration of immobility in the FST in open
space forced swim test model of depression in mice [47]. In
the present study, we found that administration of rutin to
the MS mice significantly reduced immobilization time in
the FST. However, the exact mechanisms of action involved
in antidepressant-like effects of rutin have not yet been
established.
The hippocampus is a part of the limbic system which
plays an important role in the pathophysiology of depression
[9, 48, 49]. In the study by Parashar et al., exposure of mice to
unpredictable chronic stress was associated with a significant
increase in the hippocampal CA3 neurodegeneration [11].
Ekova et al. reported dystrophic lesions in the hippocampal
CA1 and CA3 neurons in mice exposed to stressful condition
[12]. In the case of clinical studies, it has been determined
that brain MRI images of patients with depression show
changes in hippocampal volume and density of CA1 and
CA3 pyramidal neurons [10, 50]. In line with the abovemen-
tioned studies, our results showed that MS is associated with
neurodegeneration in the pyramidal area of the hippocam-
pus. We found that MS decreased the diameter of the CA3
area as well as increased the percentage of dark neurons in
the hippocampus.
It has been demonstrated that rutin prevented the death
and apoptosis of neurons and reduced the production of free
radicals and reactive oxygen species in the brain of
doxorubicin-receiving mice, suggesting neuroprotective
effects for this compound [28]. Oboh et al. have reported that
rutin possessed neuroprotective effects against cadmium-
induced neurotoxicity [27]. Our findings showed that admin-
istration of rutin to the MS mice significantly increased the
diameter of the CA3 area and decreased the percentage of
dark neurons in this area. In light of the above, it seems that
(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j) (k) (l)
(m) (n)
Figure 6: Representative features from dark neurons in the CA3 region of the hippocampus pyramidal area. (a) Control, (b) MS, (c) rutin 10
(control), (d) rutin 10 (MS), (e) rutin 50 (control), (f) Rutin 50 (MS), (g) rutin 100 (control), (h) rutin 100 (MS), (i) NMDA 150 (control), (j)
ketamine 0.25 (control), (k) NMDA 150 (MS), (l) ketamine 0.25 (MS), (m) rutin 10+ketamine (MS), and (n) rutin 100+NMDA (MS). H&E
staining (scale bar = 25micrometer).
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antidepressant-like activity of rutin probably is due to its pro-
tective effects on hippocampal CA3 neurons. However, the
determination of the possible mechanisms involved in this
neuroprotection has not been determined and further
researches are warranted for introducing the exact mecha-
nism of action of rutin.
Glutamate is a major primary chemical mediator in the
brain [51, 52]. Glutamate’s NMDA receptors are one of the
important mediators of synaptic plasticity and play an
important role in the neurobiological mechanisms of depres-
sion [53, 54]. Previous clinical and preclinical studies have
demonstrated that administration of NMDA antagonists
attenuated depressive (-like) behaviors [16, 55]. It has been
determined that acute administration of ketamine possesses
rapid antidepressant (-like) effects [56, 57]. In this regard, lit-
erature said that NMDA agonists provoked depressive-like
behaviors in rodents [58]. Our findings showed that coad-
ministration of NMDA receptor antagonist (ketamine) with
a subeffective dose of rutin did not significantly potentiated
the antidepressant-like effect of rutin. However, coadminis-
tration of an effective dose of rutin plus NMDA attenuated
the antidepressant-like effect of rutin at an effective dose,
indicating that NMDA to some extent mediated the
antidepressant-like effect of rutin. Ample evidence demon-
strated that exposure to stressful conditions increased the
expression of the NR1 and NR2 subunits of the hippocampal
NMDA receptor [15, 59]. Results of the present study showed
that early life stress is associated with the increase in the
expression of NR2A and NR2B subunits of the NMDA
receptors indicating the role of NMDA receptors in the mod-
ulation of depressive-like behaviors following maternal sepa-
ration paradigm. Our findings showed that rutin significantly
decreased the expression of NR2B and NR2A subunits of
NMDA receptor in MS mice.
5. Conclusion
Based on the results of the present study, rutin, partially at
least, through NMDA receptors possessed an antidepressant-
like effect in maternally separated mice. We showed that
rutin attenuated the negative effects of MS on the hippocam-
pal CA3 area, decreasing the number of dark neurons and
increasing the diameter of this area.
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